Louise Campbell leads a discussion about challenges in provider-patient communication with Shira Zelber-Sagi and Mike Betel, who chaired a session on this topic at the EASL Congress 2024, and Tom Marjot and Jose Willemse, who were panelists for the discussion.
In this closing conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi and podcast co-hosts Louise Campbell and Roger Green consider what the guidelines might foretell in changes in provider education, structure of patient visits and treatment in less affluent or medically advanced countries.
For most of this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi discuss key issues related to pharmacology and prescribing choices. At the end, the focus shifts to the guidelines’ overall benefits and some new kinds of education they call for.
In this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi discuss some of the guidelines’ key goals and issues surrounding the screening, diagnosis and management of MASLD patients.
In this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi explain how the guidelines process benefitted from the close collaboration between EASL, EASD, and EASO.
Two of the co-authors of the upgraded MASLD Clinical Practice Guidelines (CPG), Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the guidelines.
Co-authors Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the new MASLD Clinical Practice Guidelines from EASL, EASDand EASO.
This conversation covers some of the other major drug development stories from the EASL Congress 2024, with special focus on denifenstat, ION-224 and TAK-227, plus a look at the SPECIAL study on bariatric surgery and cirrhosis.
This conversation explores issues regarding incretin agonists and discusses results from the efruxiermin late-breaker at the EASL Congress 2024.
This conversation focuses on the tirzepatide late-breaker at the EASL Congress 2024 and broadens into a discussion of the other “Twin-cretins,” all of which are GLP-glucagon combinations.
